相关实验视频
Updated: Jul 19, 2026

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
Published on: July 10, 2017
重组ADAMTS13用于免疫性血栓性血栓性缺血紫外线
Pavan K Bendapudi1, Brody H Foy1, Sarah B Mueller1
1From the Blood Transfusion Service (P.K.B., K.N.R., P.A.R.B., W.H.D., J.A.S., R.S.M.), the Division of Hematology (P.K.B., R.K.L., W.H.D.), the Department of Pathology (B.H.F., J.L., M.Y.C., J.R.S., J.H.), and the Division of Cardiology (E.S.L., R.L.G.), Massachusetts General Hospital, the Division of Hemostasis and Thrombosis (P.K.B., L.M.F., K.E.B., I.T., S.C.W.) and the Division of Hematology and Apheresis Service (B.J.C.), Beth Israel Deaconess Medical Center, and Harvard Medical School (P.K.B., J.L., M.Y.C., E.S.L., R.L.G., I.T., S.C.W., B.J.C., J.R.S., K.N.R., P.A.R.B., R.K.L., J.H., W.H.D., J.A.S., R.S.M.), Boston, the Broad Institute of MIT and Harvard, Cambridge (P.K.B.), the Division of Hematology and Oncology, Lahey Hospital and Medical Center, Burlington (D.P.), and the Department of Hematology and Clinical Oncology (A.R.A.) and the Department of Pathology, Transfusion/Apheresis Medicine Services (S.H., C.A.), UMass Chan Medical School-Baystate Health, Springfield - all in Massachusetts; the Department of Laboratory Medicine and Pathology, University of Washington, Seattle (B.H.F.); and Versiti Blood Center of Wisconsin, Milwaukee (S.B.M., W.C., K.D.F.).
再组合的人类ADAMTS13 (rADAMTS13) 疗法在免疫血栓性血栓性斑疹 (iTTP) 耐其他治疗的患者中迅速缓解了疾病活动. 通过形成免疫复合体和促进自身抗体清除,rADAMTS13可能提供一种新的辅助治疗方法.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 免疫性血栓性血栓性缺血性紫外线 (iTTP) 的特征是对ADAMTS13的自身抗体,导致微血管血栓症.
- 目前对耐火性iTTP的治疗方法有限,这凸显了对新型治疗策略的需求.
研究的目的:
- 在耐火性iTTP患者中研究复合人类ADAMTS13 (rADAMTS13) 的临床疗效和潜在机制.
主要方法:
- 病例报告详细介绍了rADAMTS13给一个严重病情的iTTP患者的使用情况.
- 分析疾病活动标志物和治疗后免疫复合体形成的分析.
主要成果:
- rADAMTS13的使用导致iTTP疾病活动的快速抑制,并使患者完全康复.
- rADAMTS13诱导免疫复合物形成,可能和并促进抗ADAMTS13自身抗体的清除.
结论:
- rADAMTS13显示出作为一种新型辅助疗法的潜力,用于患有严重或不耐药的免疫血栓性血栓塞性紫外线的患者.
- 该机制可能涉及免疫复合体的形成和随后的自身抗体清除.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Venous Thrombosis III: Interprofessional Care

